Free Trial

Nanobiotix (NBTX) Stock Price, News & Analysis

-0.47 (-8.12%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
4,285 shs
Average Volume
25,456 shs
Market Capitalization
$250.73 million
P/E Ratio
Dividend Yield
Price Target

Nanobiotix MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
106.8% Upside
$11.00 Price Target
Short Interest
0.12% of Shares Sold Short
Dividend Strength
News Sentiment
1.89mentions of Nanobiotix in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.82) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.80 out of 5 stars

Medical Sector

683rd out of 913 stocks

Pharmaceutical Preparations Industry

326th out of 429 stocks

NBTX stock logo

About Nanobiotix Stock (NASDAQ:NBTX)

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

NBTX Stock Price History

NBTX Stock News Headlines

NBTX Nanobiotix S.A.
Nanobiotix initiated with an Outperform at Leerink
See More Headlines
Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$39.18 million
Book Value
($0.04) per share


Free Float
Market Cap
$272.88 million
Not Optionable
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Laurent Levy Ph.D. (Age 51)
    Co-Founder, President of the Executive Board & CEO
    Comp: $774.87k
  • Mr. Bart Van Rhijn (Age 51)
    CFO & Member of Executive Board
    Comp: $682.2k
  • Ms. Anne-Juliette Hermant M.A. (Age 50)
    Chief People Officer & Member of Executive Board
    Comp: $385.23k
  • Dr. Louis Kayitalire M.D. (Age 66)
    Chief Medical Officer
    Comp: $543.6k
  • Mr. Earl J. Bergey Ph.d. (Age 69)
  • Mr. Craig West CFA
    Senior Vice President of Investor Relations
  • Mr. Brandon Owens
    VP of Strategic Marketing & Corporate Communication
  • Mr. Patrick Tricoli M.B.A.
    Pharm.D., Global Head of Business Development
  • Ms. Margaret Galluzzi
    VP & Global Head of Clinical Operations
  • Mr. Ventzislav Vassilev M.D.
    VP & Global Head of Safety Vigilance

NBTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Nanobiotix stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NBTX shares.
View NBTX analyst ratings
or view top-rated stocks.

What is Nanobiotix's stock price target for 2024?

3 brokers have issued twelve-month price targets for Nanobiotix's stock. Their NBTX share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 106.8% from the stock's current price.
View analysts price targets for NBTX
or view top-rated stocks among Wall Street analysts.

How have NBTX shares performed in 2024?

Nanobiotix's stock was trading at $7.28 at the start of the year. Since then, NBTX shares have decreased by 26.9% and is now trading at $5.32.
View the best growth stocks for 2024 here

When did Nanobiotix IPO?

Nanobiotix (NBTX) raised $95 million in an initial public offering on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO.

How do I buy shares of Nanobiotix?

Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBTX) was last updated on 6/12/2024 by Staff

From Our Partners